RZLT实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 04:00):

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States...

Stats
今日成交量	162 061
平均成交量	349 288
市值	114.36M
EPS	$0 ( 2024-02-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.59
ATR14	$0.0220 (0.78%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Roberts Brian Kenneth	Buy	500	Common Shares
2022-07-22	Handok, Inc.	Buy	3 157 895	Common Shares
2021-10-15	Handok, Inc.	Buy	769 231	Common Shares
2024-03-15	Evans Daron	Buy	20 000	Common Shares
2024-03-14	Roberts Brian Kenneth	Buy	10 000	Common Shares

INSIDER POWER
100.00
Last 96 transactions
Buy: 107 305 216 \| Sell: 58 571 575

音量相关性

長: -0.11 (neutral)

短: 0.90 (strong)

Signal:(54.094) Same movement expected

Rezolute, Inc. 相关性

10 最正相关
XBIT	0.97
MTEK	0.968
VNOM	0.967
FANG	0.963
ENTX	0.961
PRIM	0.958
APP	0.954
SVFAU	0.954
IXAQ	0.951
AEAC	0.951

10 最负相关
HCDIP	-0.96
AKTX	-0.959
HAIN	-0.95
EMBC	-0.947
SPTN	-0.94
SHEN	-0.939
XPON	-0.936
UONEK	-0.934
PEAR	-0.934
BPTH	-0.933

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Rezolute, Inc. 相关性 - 货币/商品

-0.62
( weak negative )

-0.65
( moderate negative )

0.00
( neutral )

-0.75
( moderate negative )

-0.45
( neutral )

0.22
( neutral )

Rezolute, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-382 000 (0.00 %)
EPS:	$-1.010

FY	2023
营收:	$0
毛利润:	$-382 000 (0.00 %)
EPS:	$-1.010

FY	2022
营收:	$0
毛利润:	$-256 000 (0.00 %)
EPS:	$-2.13

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.72

Financial Reports:

No articles found.

Rezolute, Inc.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.